Tim Demuth

4.5k total citations
43 papers, 3.2k citations indexed

About

Tim Demuth is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Tim Demuth has authored 43 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 23 papers in Oncology and 9 papers in Genetics. Recurrent topics in Tim Demuth's work include Glioma Diagnosis and Treatment (8 papers), Cancer-related Molecular Pathways (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Tim Demuth is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Cancer-related Molecular Pathways (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Tim Demuth collaborates with scholars based in United States, Japan and Canada. Tim Demuth's co-authors include Michael E. Berens, Dominique B. Hoelzinger, Mitsutoshi Nakada, Satoko Nakada, Nhan L. Tran, Stuart D. Shumway, Christian Beaudry, Andrew M. Stein, Leonard M. Sander and David L. Mobley and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Tim Demuth

43 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim Demuth United States 24 2.0k 1.2k 624 608 542 43 3.2k
Tatsuya Ozawa Japan 26 1.7k 0.9× 1.0k 0.9× 1.2k 1.9× 1.4k 2.2× 374 0.7× 49 3.5k
Motoo Nagane Japan 28 2.5k 1.2× 1.3k 1.1× 959 1.5× 1.3k 2.1× 280 0.5× 113 4.3k
Frits Thorsen Norway 36 1.6k 0.8× 955 0.8× 972 1.6× 1.2k 2.0× 268 0.5× 84 4.0k
Igor Garkavtsev United States 25 2.9k 1.5× 1.2k 1.0× 1.2k 1.8× 406 0.7× 251 0.5× 32 4.1k
Bryan W. Day Australia 28 1.4k 0.7× 606 0.5× 662 1.1× 690 1.1× 315 0.6× 82 2.4k
Sara Piccirillo Italy 23 2.8k 1.4× 1.8k 1.5× 1.8k 2.8× 1.9k 3.1× 319 0.6× 48 5.0k
Andrew R. Reynolds United Kingdom 31 2.8k 1.4× 1.2k 1.0× 1.2k 1.8× 186 0.3× 402 0.7× 36 4.2k
Dominique B. Hoelzinger United States 18 1.2k 0.6× 499 0.4× 524 0.8× 400 0.7× 353 0.7× 27 2.1k
Joseph Celestino United States 20 1.5k 0.8× 931 0.8× 741 1.2× 844 1.4× 211 0.4× 46 2.7k
Mizuhiko Terasaki Japan 16 2.2k 1.1× 2.7k 2.3× 1.1k 1.8× 1.3k 2.1× 377 0.7× 47 4.6k

Countries citing papers authored by Tim Demuth

Since Specialization
Citations

This map shows the geographic impact of Tim Demuth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Demuth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Demuth more than expected).

Fields of papers citing papers by Tim Demuth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Demuth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Demuth. The network helps show where Tim Demuth may publish in the future.

Co-authorship network of co-authors of Tim Demuth

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Demuth. A scholar is included among the top collaborators of Tim Demuth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Demuth. Tim Demuth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mazières, Julien, Paul K. Paik, Enriqueta Felip, et al.. (2021). OA05.03 Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A. Journal of Thoracic Oncology. 16(1). S5–S5. 1 indexed citations
3.
Mazières, Julien, Paul K. Paik, Enriqueta Felip, et al.. (2020). 1283P Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A. Annals of Oncology. 31. S828–S829. 4 indexed citations
4.
Tabernero, Josep, Robin M.J.M. van Geel, Tormod Kyrre Guren, et al.. (2016). O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results. Annals of Oncology. 27. ii127–ii127. 5 indexed citations
5.
6.
Gomez‐Roca, Carlos, Jean‐Pierre Delord, Caroline Robert, et al.. (2014). Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study. Annals of Oncology. 25. iv182–iv182. 39 indexed citations
7.
Krop, Ian E., Tim Demuth, Tina Guthrie, et al.. (2012). Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 30(19). 2307–2313. 251 indexed citations
8.
Sarcar, Bhaswati, Soumen Kahali, Antony Prabhu, et al.. (2011). Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines. Molecular Cancer Therapeutics. 10(12). 2405–2414. 91 indexed citations
9.
Fouladi, Maryam, Jeff Olson, Clinton F. Stewart, et al.. (2010). A phase I trial of MK-0752 in children with recurrent or refractory CNS malignancies: A Pediatric Brain Tumor Consortium study.. Journal of Clinical Oncology. 28(15_suppl). 9502–9502. 2 indexed citations
10.
Watters, James, Chun Cheng, Pradip K. Majumder, et al.. (2009). De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model. Cancer Research. 69(23). 8949–8957. 31 indexed citations
11.
Nakada, Mitsutoshi, Eric M. Anderson, Tim Demuth, et al.. (2009). The phosphorylation of ephrin‐B2 ligand promotes glioma cell migration and invasion. International Journal of Cancer. 126(5). 1155–1165. 83 indexed citations
12.
Demuth, Tim, Jessica L. Rennert, Dominique B. Hoelzinger, et al.. (2008). Glioma cells on the run – the migratory transcriptome of 10 human glioma cell lines. BMC Genomics. 9(1). 54–54. 54 indexed citations
13.
Hoelzinger, Dominique B., et al.. (2007). Autotaxin: a secreted autocrine/paracrine factor that promotes glioma invasion. Journal of Neuro-Oncology. 86(3). 297–309. 46 indexed citations
14.
Stein, Andrew M., Michal O. Nowicki, Tim Demuth, et al.. (2007). Estimating the cell density and invasive radius of three-dimensional glioblastoma tumor spheroids grown in vitro. Applied Optics. 46(22). 5110–5110. 9 indexed citations
15.
Hoelzinger, Dominique B., Tim Demuth, & Michael E. Berens. (2007). Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment. JNCI Journal of the National Cancer Institute. 99(21). 1583–1593. 290 indexed citations
16.
Nakada, Mitsutoshi, Satoko Nakada, Tim Demuth, et al.. (2007). Molecular targets of glioma invasion. Cellular and Molecular Life Sciences. 64(4). 458–478. 308 indexed citations
17.
Reavie, Linsey B., Tim Demuth, Dominique B. Hoelzinger, et al.. (2006). Glioma invadomics - identification and validation of novel targets for glioma invasion in-vivo. Cancer Research. 66. 434–434. 1 indexed citations
18.
Deisboeck, Thomas S., Tim Demuth, & Yuri Mansury. (2005). Correlating Velocity Patterns With Spatial Dynamics In Glioma Cell Migration. Acta Biotheoretica. 53(3). 181–190. 5 indexed citations
19.
Demuth, Tim & Michael E. Berens. (2004). Molecular Mechanisms of Glioma Cell Migration and Invasion. Journal of Neuro-Oncology. 70(2). 217–228. 408 indexed citations
20.
Mariani, Luigi, Christian Beaudry, Wendy S. McDonough, et al.. (2001). Glioma Cell Motility is Associated with Reduced Transcription of Proapoptotic and Proliferation Genes: A cDNA Microarray Analysis. Journal of Neuro-Oncology. 53(2). 161–176. 155 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tatsuya Ozawa Breakdown of academic impact, for papers by Motoo Nagane Breakdown of academic impact, for papers by Frits Thorsen Breakdown of academic impact, for papers by Igor Garkavtsev Breakdown of academic impact, for papers by Bryan W. Day Breakdown of academic impact, for papers by Sara Piccirillo Breakdown of academic impact, for papers by Andrew R. Reynolds Breakdown of academic impact, for papers by Dominique B. Hoelzinger Breakdown of academic impact, for papers by Joseph Celestino Breakdown of academic impact, for papers by Mizuhiko Terasaki
Rankless by CCL
2026